利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.027 秒)

    Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use
    3.
    发明申请
    Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use 有权
    抗干扰素α单克隆抗体及其使用方法

    公开(公告)号：US20080160030A1

    公开(公告)日：2008-07-03

    申请号：US11883961

    申请日：2006-02-09

    申请人： Jacques F. Banchereau ,  Kiley Prilliman ,  Virginia Pascual ,  Anna Karolina Palucka

    发明人： Jacques F. Banchereau ,  Kiley Prilliman ,  Virginia Pascual ,  Anna Karolina Palucka

    IPC分类号： A61K39/395 ,  C07K16/24 ,  C07H21/00 ,  C07K7/08 ,  C07H21/02 ,  C07K7/06 ,  C12N5/00

    CPC分类号： C07K16/249 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

    摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

    摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的蛋白质亚型的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。

    REPROGRAMMING IMMUNE ENVIRONMENT IN BREAST CANCER VIA DENDRITIC CELLS
    5.
    发明申请
    REPROGRAMMING IMMUNE ENVIRONMENT IN BREAST CANCER VIA DENDRITIC CELLS 审中-公开
    通过感染细胞转染乳腺癌免疫环境

    公开(公告)号：US20130064855A1

    公开(公告)日：2013-03-14

    申请号：US13611976

    申请日：2012-09-12

    申请人： Anna Karolina Palucka ,  Jacques F. Banchereau ,  Florentina Marches ,  Chun Yu ,  SangKon Oh ,  Te-Chia Wu

    发明人： Anna Karolina Palucka ,  Jacques F. Banchereau ,  Florentina Marches ,  Chun Yu ,  SangKon Oh ,  Te-Chia Wu

    IPC分类号： A61K31/716 ,  A61K39/00 ,  A61P35/00

    CPC分类号： A61K39/0011 ,  A61K31/716 ,  A61K35/15 ,  A61K2039/5154

    摘要： Compositions and methods for the treatment of cancer disclosed herein. The method of the present invention comprises administration of compositions comprising β-glucan, a natural ligand for dectin-1, to block OX40L expression on tumor associated mDCs by blocking STAT6 phosphorylation. The β-glucan-treated mDCs secrete higher levels of IL-12p70 and do not expand TNFα and IL-13-producing CD4+ T cells, further resulting in inhibition of Th2 responses. Thus, compositions disclosed herein reprogram the function of mDCs in breast tumor microenvironment and turn tumor promoting Th2-type chronic inflammation into Th1-type acute inflammation that are able to reject tumors. The present invention finds particular uses for the intratumoral administration of the composition thereby directly binding to and directing a Th1-type acute inflammation.

    摘要翻译： 本文公开的用于治疗癌症的组合物和方法。 本发明的方法包括施用包含葡聚糖的组合物，其是dectin-1的天然配体，通过阻断STAT6磷酸化阻断肿瘤相关mDC上的OX40L表达。 葡聚糖处理的mDC分泌更高水平的IL-12p70，不扩大TNFα和IL-13产生的CD4 + T细胞，进一步导致Th2应答的抑制。 因此，本文公开的组合物重新编码mDC在乳腺肿瘤微环境中的功能，并将肿瘤促进Th2型慢性炎症转化为能够排斥肿瘤的Th1型急性炎症。 本发明特别用于肿瘤内施用组合物，从而直接结合并导向Th1型急性炎症。

    Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
    6.
    发明申请
    Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer 审中-公开
    胸腺基质淋巴细胞生成素（TSLP）和OX40配体在癌症

    公开(公告)号：US20120020960A1

    公开(公告)日：2012-01-26

    申请号：US13189244

    申请日：2011-07-22

    申请人： Anna Karolina Palucka ,  Jacques F. Banchereau

    发明人： Anna Karolina Palucka ,  Jacques F. Banchereau

    IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P29/00 ,  A61K38/16 ,  C07K16/24

    CPC分类号： A61K45/06 ,  A61K39/395 ,  C07K16/24

    摘要： Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13+TNFα+IL-10negCD4+ T cells (Th2 cells). Thus, TSLP, and/or down-stream pathways, represent novel potential therapeutic targets against human breast cancer.

    摘要翻译： 本文提供了人类乳腺癌免疫治疗方法的组合物和方法。 胸腺基质淋巴细胞生成素（TSLP）和/或OX40L的任何拮抗剂通过阻断暴露于乳腺癌的DCs上调OX40L从而抑制其产生炎症性IL-13 +TNFα+ IL- 10negCD4 + T细胞（Th2细胞）。 因此，TSLP和/或下游途径代表了针对人类乳腺癌的新型潜在治疗靶点。

    USE OF ALLOGENEIC CELL LINES TO LOAD ANTIGEN-PRESENTING CELLS TO ELICIT OR ELIMINATE IMMUNE RESPONSES
    8.
    发明申请
    USE OF ALLOGENEIC CELL LINES TO LOAD ANTIGEN-PRESENTING CELLS TO ELICIT OR ELIMINATE IMMUNE RESPONSES 审中-公开
    使用同种异体细胞系负载抗原呈递细胞以免疫或免疫免疫应答

    公开(公告)号：US20110268767A1

    公开(公告)日：2011-11-03

    申请号：US13169456

    申请日：2011-06-27

    申请人： Jacques F. Banchereau ,  Frederic Berard ,  Patrick Blanco ,  Eve-Marie Neidhart-Berard ,  Mahyar Nouri-Shirazi ,  Anna Karolina Palucka

    发明人： Jacques F. Banchereau ,  Frederic Berard ,  Patrick Blanco ,  Eve-Marie Neidhart-Berard ,  Mahyar Nouri-Shirazi ,  Anna Karolina Palucka

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/06 ,  A61P37/04 ,  C12N5/0783 ,  C12Q1/02

    CPC分类号： C12N5/0639 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/0011 ,  A61K2035/122 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/57 ,  C12N5/064

    摘要： Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful in the management of cancer. Antigen-loaded dendritic cells prepared as described here can prime naïve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dendritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses.

    摘要翻译： 描述了载有来自死亡或死亡细胞（包括同种异体细胞系）的抗原的新型抗原呈递细胞，包括但不限于树突状细胞，以及制备这种抗原呈递细胞的方法。 这些负载的抗原呈递细胞在人体中诱导治疗性免疫应答。 这种负载的抗原呈递细胞可用于治疗癌症。 如本文所述制备的抗原负载的树突状细胞可以使初始的T细胞分化为能够识别多次和/或共享肿瘤抗原的效应细胞，所述多个和/或共享的肿瘤抗原在用于加载树突状细胞的肿瘤细胞上表达，和/或在其他 肿瘤细胞。 通过暴露于如本文所述制备的抗原负载的树突状细胞产生的细胞毒性T细胞可用于过继疗法。 如本文所述，这种对不同细胞（例如肿瘤细胞）共有的多种抗原的反应诱导是重要的，因为它导致广泛的免疫应答。

    Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
    10.
    发明授权
    Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses 失效
    使用同种异体细胞系来加载抗原呈递细胞以引发或消除免疫应答

    公开(公告)号：US07988963B1

    公开(公告)日：2011-08-02

    申请号：US10110553

    申请日：2000-10-16

    申请人： Jacques F. Banchereau ,  Frederic Berard ,  Patrick Blanco ,  Eve-Marie Neidhart-Berard ,  Mahyar Nouri-Shirazi ,  Anna Karolina Palucka

    发明人： Jacques F. Banchereau ,  Frederic Berard ,  Patrick Blanco ,  Eve-Marie Neidhart-Berard ,  Mahyar Nouri-Shirazi ,  Anna Karolina Palucka

    IPC分类号： A61K35/14 ,  C12N5/078 ,  C12N5/0784 ,  C12N5/0786 ,  C12N5/0783

    CPC分类号： C12N5/0639 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/0011 ,  A61K2035/122 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/57 ,  C12N5/064

    摘要： Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful in the management of cancer. Antigen-loaded dendritic cells prepared as described here can prime naïve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dendritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses.

    摘要翻译： 描述了载有来自死亡或死亡细胞（包括同种异体细胞系）的抗原的新型抗原呈递细胞，包括但不限于树突状细胞，以及制备这种抗原呈递细胞的方法。 这些负载的抗原呈递细胞在人体中诱导治疗性免疫应答。 这种负载的抗原呈递细胞可用于治疗癌症。 如本文所述制备的抗原负载的树突状细胞可以使初始的T细胞分化为能够识别多次和/或共享肿瘤抗原的效应细胞，所述多个和/或共享的肿瘤抗原在用于加载树突状细胞的肿瘤细胞上表达，和/或在其他 肿瘤细胞。 通过暴露于如本文所述制备的抗原负载的树突状细胞产生的细胞毒性T细胞可用于过继疗法。 如本文所述，这种对不同细胞（例如肿瘤细胞）共有的多种抗原的反应诱导是重要的，因为它导致广泛的免疫应答。